recommended for detection of Thr 34 phosphorylated DARPP-32 of mouse, rat and human origin by WB and IP; also reactive with additional species, including bovine and canine
Modification
Phosphoralated
Modification Notes
Dopaminergic signaling pathways, which are essential for multiple brain functions, are abnormal in several neurological disorders, such as schizophrenia, Parkinson’s disease and drug abuse. DARPP-32 is abundant in neurons that receive dopaminergic input. Activation of PKA and the consequent phosphorylation of DARPP-32 on Thr 34 occurs in response to dopamine acting upon D1-like receptors. Dopamine interaction with D2-like receptors results in the inhibition of PKA activation, the activation of protein phosphatase 2B and the consequent dephosphorylation of DARPP-32 at Thr 34. Phosphorylated DARPP-32 at Thr 34 is a potent inhibitor of PP-1. Phosphorylation of DARPP-32 on Ser 137 by casein kinase inhibits the dephos-phorylation of Thr 34 by calcineurin. Phosphorylation of DARPP-32 on Thr 75 by CdK5 inhibits PKA by a competitive mechanism in vitro. Decreasing the phosphorylaton of DARPP-32 Thr 75 increases the dopamine-induced phosphorylation of PKA substrates.
Key Feature
Clonality
Polyclonal
Isotype
IgG
Host Species
Rabbit
Tested Applications
WBIP
See 1 citations for p-DARPP-32Antibody (Thr 34):
Species Reactivity
HumanMouseRat
Concentration
1mg/ml
Purification
Affinity purified
Target Information
Alternative Names
recommended for detection of Thr 34 phosphorylated DARPP-32 of mouse rat and human origin by WB and IP also reactive with additional species including bovine and canine
Tissue Specificity
recommended for detection of Thr 34 phosphorylated DARPP-32 of mouse, rat and human origin by WB and IP; also reactive with additional species, including bovine and canine